Universität zu Köln

Striefler, Jana K., Reissig, Timm M., Kunzmann, Volker, Westphalen, C. Benedikt, Boeck, Stefan, Ettrich, Thomas J., Lutz, Manfred P., Waldschmidt, Dirk T., Brunner, Thomas, Uhl, Waldemar, Sinn, Marianne and Siveke, Jens T. (2022). Pancreatic cancer Clinical research projects of the German oncology groups (ACO, AIO, and ARO). Onkologe, 28 (SUPPL 1). S. 30 - 36. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0415

Full text not available from this repository.

Abstract

Background: The incidence of pancreatic cancer (PC) is increasing. Due to a combination of therapeutic resistance and to advanced disease already at diagnosis, PC remains one of the most fatal malignant solid tumors with a 5-year survival rate of only 8-9%. Objectives: The German oncology study groups offer a broad portfolio of clinical trials. We present the most current projects of Arbeitsgemeinschaft Chirurgische Onkologie (ACO), Arbeitsgemeinschaft Internistische Onkologie (AIO), and Arbeitsgemeinschaft Radiologische Onkologie (ARO) in PC including recruiting studies as well as those envisaged or recently completed. Results: Combination chemotherapy is still the backbone of PC therapy. In localized disease, curatively intended resection followed by adjuvant chemotherapy remains standard in fit patients (e.g., modified FOLFIRINOX, gemcitabine-based). In addition, clinical trial activities focus on the role of perioperative therapy in PC. Recent clinical trials analyze the benefit in the (borderline) resectable (NEONAX), locally advanced (NEOLAP), and oligometastatic (METAPANC, HOLIPANC) setting. In metastatic PC, intensified chemotherapeutic protocols and combined epigenetic and immune targeting concepts are currently being evaluated. Conclusion: Taking into account the relevant therapeutic resistance of PC, new therapeutic concepts are needed to further ameliorate the prognosis. The role of perioperative therapy needs to be further clarified and is the objective of recent studies.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Striefler, Jana K. UNSPECIFIED UNSPECIFIED UNSPECIFIED Reissig, Timm M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Kunzmann, Volker UNSPECIFIED UNSPECIFIED UNSPECIFIED Westphalen, C. Benedikt UNSPECIFIED UNSPECIFIED UNSPECIFIED Boeck, Stefan UNSPECIFIED UNSPECIFIED UNSPECIFIED Ettrich, Thomas J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Lutz, Manfred P. UNSPECIFIED UNSPECIFIED UNSPECIFIED Waldschmidt, Dirk T. UNSPECIFIED UNSPECIFIED UNSPECIFIED Brunner, Thomas UNSPECIFIED UNSPECIFIED UNSPECIFIED Uhl, Waldemar UNSPECIFIED UNSPECIFIED UNSPECIFIED Sinn, Marianne UNSPECIFIED UNSPECIFIED UNSPECIFIED Siveke, Jens T. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-693257
DOI:	10.1007/s00761-022-01107-w
Journal or Publication Title:	Onkologe
Volume:	28
Number:	SUPPL 1
Page Range:	S. 30 - 36
Date:	2022
Publisher:	SPRINGER HEIDELBERG
Place of Publication:	HEIDELBERG
ISSN:	1433-0415
Language:	German
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language PACLITAXEL PLUS GEMCITABINE; INDUCTION CHEMOTHERAPY; MULTICENTER; FOLFIRINOX; TRIAL Multiple languages Oncology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/69325